Table 2.3.
Comparing thrombotic complications, COVID treatment modalities and outcomes, among cancer and Non-cancer control cohorts and among different type of cancer
| Treatment | No Cancer N = 50,568 |
Unspecified Cancer N = 541 |
Hematological N = 147 |
Solid Cancer N = 288 |
P Value |
|---|---|---|---|---|---|
| Thrombotic Complications | |||||
| Yes | 157 (0.31) | 1 (0.2) | 1 (0.68) | - | 0.58 |
| No | 50,411 (99.7) | 540 (99.8) | 146 (99.3) | 288 (100) | |
| Cardio Vascular Complication | |||||
| Yes | 562 (1.1) | 13 (2.4) | 3 (2) | 7 (2.4) | 0.004 |
| No | 50,006 (98.9) | 528 (97.6) | 144 (98) | 281 (97.6) | |
| Remdesivir | |||||
| Yes | 16,579 (32.79) | 76 (14.05) | 33 (22.45) | 60 (20.8) | < 0.001 |
| No | 33,989 (67.2) | 465 (85.9) | 114 (77.55) | 228 (79.17) | |
| Steroids | |||||
| Yes | 28,920 (57.19) | 255 (47.13) | 71 (48.3) | 105 (36.46) | < 0.001 |
| No | 21,648 (42.8) | 286 (52.87) | 76 (51.7) | 183 (63.54 | |
| Anticoagulants | |||||
| Yes | 28,916 (57.18) | 257 (47.5) | 68 (46.2) | 127 (44.10) | < 0.001 |
| No | 21,652 (42.8) | 284 (52.5) | 79 (53.7) | 161 (55.9) | |
| Supportive Oxygen Therapy | |||||
| Yes | 24,988 (49.4) | 259 (47.87) | 69 (46.9) | 129 (44.7) | 0.105 |
| No | 25,580 (50.6) | 282 (52.13) | 78 (53.06) | 159 (55.2) | |
| Invasive Mechanical Ventilation | |||||
| Yes | 1554 (3.1) | 24 (4.4) | 5 (3.4) | 7 (2.4) | 0.28 |
| No | 49,014 (96.9) | 517 (95.6) | 142 (96.6) | 281 (97.6) | |
| ICU-Organ support requireda | |||||
| Yes | 5291 (10.46) | 65 (12.01) | 19 (12.9) | 43 (14.9) | 0.040 |
| No | 45,277 (89.54) | 476 (87.99) | 128 (87.07) | 245 (85.07) | |
| Outcome | |||||
| Discharged to home | 40,823 (80.7) | 372 (68.8) | 98 (66.7) | 183 (63.5) | < 0.001 |
| Death | 5977 (11.8) | 105 (19.4) | 31 (21.09) | 72 (25) | |
| Transferred /LAMA | 3768 | 64 (11.8) | 18 (12.2) | 33 11.46) |
aICU-Organ support is a composite outcome taking into account the requirement of ICU admission during hospital stay, ECHMO Support, Vasopressor and Renal Replacement